Is Acumen Pharmaceuticals (NASDAQ:ABOS) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know

Simply Wall StJul 17 11:47 ET

Infor Acquires Acumen and Albanero

Infor Acquisitions Strengthen Industry-Centric Data Foundation NEW YORK, July 11, 2024 /PRNewswire/ -- Infor, the industry cloud company, has completed the acquisitions of Albanero, a data migration

PR NewswireJul 11 09:00 ET

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights From Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC) 2024

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers

GlobeNewswireJul 11 08:00 ET

Accorded Launches Latest Offering, Accorded Acumen: The Actuarial Data Transformation Platform

SAN MATEO, Calif.--(BUSINESS WIRE)--Accorded, Inc., a leader in healthcare actuarial intelligence, unveils its latest offering: Accorded Acumen. Acumen is an actuarial data transformation platform tha

BusinesswireJun 17 12:34 ET

BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11

BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 37.8% and

moomoo NewsJun 10 07:31 ET · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)

TipRanksMay 16 06:17 ET